Why Bristol-Myers Squibb Is A Buy? Acquirer’s Multiple Stock Screener Analysis

Johnny HopkinsStock ScreenerLeave a Comment

As part of our ongoing series here at The Acquirer’s Multiple, each week we focus on one of the stocks from our Stock Screeners, and why it’s a ‘buy’ based on key fundamentals.

One of the cheapest stocks in our Stock Screeners is:

Bristol-Myers Squibb Co (BMY)

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.

A quick look at the share price history (below) over the past twelve months shows that the price is down 28.40%. Here’s why the company is undervalued.

BMY Chart

BMY data by YCharts

Key Stats

Market Cap: $102.89 Billion

Enterprise Value: $132.07 Billion

Operating Earnings

Operating Earnings: $8.45 Billion

Acquirer’s Multiple

Acquirer’s Multiple: 15.60

Free Cash Flow (TTM)

Free Cash Flow: $12.65 Billion

FCF/EV Yield %:

FCF/EV Yield: 12.30

Shareholder Yield %:

Shareholder Yield: 9.60

Other Indicators

Piotroski F Score: 6.00

Altman Z-Score (TTM): 2.297

ROA (5 Year Avge%): 9

For all the latest news and podcasts, join our free newsletter here.

FREE Stock Screener

Don’t forget to check out our FREE Large Cap 1000 – Stock Screener, here at The Acquirer’s Multiple:


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.